Use of letrozole to augment height outcome in pubertal boys: a retrospective chart review
-
Snigdha R. Likki
Abstract
Objectives
We describe growth patterns and predicted adult height (PAH) in pubertal boys treated with letrozole and evaluate the potential predictors of growth responses.
Methods
We performed a retrospective analysis of data from 2002 to 2020. All subjects were treated for ≥6 months and had at least 3 height measurements to calculate the growth velocity (GV) before and during treatment. We evaluated growth measurements, bone age, and biochemical parameters before, during and after treatment.
Results
A total of 59 subjects aged 12.7 (± 1.7) years old were included. At treatment initiation, bone age was 13.1 (± 1.5) years and predicted adult height (PAH) was 163.8 (± 9.9) cm compared to mid-parental height of 172.4 (± 5.8) cm. Growth velocity decreased during letrozole therapy and rebounded after completion. Sub-analysis of 26 subjects with bone age data available at baseline and at least 1 year later showed a trend to modest increase in PAH. In boys simultaneously receiving growth hormone (rhGH), the change in PAH was significantly more (3.2 cm, p<0.05) compared to those treated with letrozole alone.
Conclusions
We show that letrozole appropriately slows down skeletal maturation and GV responses are variable. Possible negative predictors include lower baseline GV and advanced bone age. A small positive trend in PAH with letrozole therapy is augmented by simultaneous use of rhGH. Future randomized controlled trials are needed to better understand which group of patients will benefit from treatment.
Acknowledgments
The authors thank Drs. Edward O. Reiter and Elizabeth Peacock – Chambers for helpful discussions along the study and critical reading of the manuscript.
-
Research funding: None declared.
-
Author contributions: SR collected, analyzed the data and drafted the manuscript. HA conceived the project, analyzed, and interpreted the data. AK contributed to design of the work and performed data analysis. KT contributed to data analysis, interpretation, and drafting of the manuscript. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: The study was granted an exemption from requiring a written informed consent due to its retrospective nature.
-
Ethical approval: This study protocol was reviewed and approved by the Institutional Review Board of Baystate Medical Center, approval number BH20-138.
References
1. Collett-Solberg, PF, Ambler, G, Backeljauw, PF, Bidlingmaier, M, Biller, BMK, Boguszewski, MCS, et al.. Diagnosis, genetics, and therapy of short stature in children: a growth hormone research society international perspective. Horm Res Paediatr 2019;92:1–14. https://doi.org/10.1159/000502231.Suche in Google Scholar
2. Sisley, S, Trujillo, MV, Khoury, J, Backeljauw, P. Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic short children. J Pediatr 2013;163:1045–51. https://doi.org/10.1016/j.jpeds.2013.04.002.Suche in Google Scholar
3. Baron, J, Sävendahl, L, De Luca, F, Dauber, A, Phillip, M, Wit, JM, et al.. Short and tall stature: a new paradigm emerges. Nat Rev Endocrinol 2015;11:735–46. https://doi.org/10.1038/nrendo.2015.165.Suche in Google Scholar
4. Greulich, W, Pyle, S. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Stanford, California: Stanford University Press; 1959.10.1097/00000441-195909000-00030Suche in Google Scholar
5. Wehkalampi, K, Vangonen, K, Laine, T, Dunkel, L. Progressive reduction of relative height in childhood predicts adult stature below target height in boys with constitutional delay of growth and puberty. Horm Res Paediatr 2007;68:99–104. https://doi.org/10.1159/000101011.Suche in Google Scholar
6. Geffner, ME. Aromatase inhibitors to augment height: continued caution and study required. J Clin Res Pediatr Endocrinol 2009;1:256–61. https://doi.org/10.4274/jcrpe.v1i6.256.Suche in Google Scholar
7. Inzaghi, E, Reiter, E, Cianfarani, S. The challenge of defining and investigating the causes of idiopathic short stature and finding an effective therapy. Horm Res Paediatr 2019;92:71–83. https://doi.org/10.1159/000502901.Suche in Google Scholar
8. Wit, JM, Oostdijk, W. Novel approaches to short stature therapy. Best Pract Res Clin Endocrinol Metab 2015;29:353–66. https://doi.org/10.1016/j.beem.2015.01.003.Suche in Google Scholar
9. Huttunen, H, Varimo, T, Huopio, H, Voutilainen, R, Tenhola, S, Miettinen, PJ, et al.. Serum testosterone and oestradiol predict the growth response during puberty promoting treatment. Clin Endocrinol 2022;96:220–6. https://doi.org/10.1111/cen.14605.Suche in Google Scholar
10. Wickman, S, Sipilä, I, Ankarberg-Lindgren, C, Norjavaara, E, Dunkel, L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743–8. https://doi.org/10.1016/s0140-6736(00)04895-9.Suche in Google Scholar
11. Hero, M, Norjavaara, E, Dunkel, L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:6396–402. https://doi.org/10.1210/jc.2005-1392.Suche in Google Scholar
12. Mauras, N, de Pijem, LG, Hsiang, HY, Desrosiers, P, Rapaport, R, Schwartz, ID, et al.. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008;93:823–31. https://doi.org/10.1210/jc.2007-1559.Suche in Google Scholar
13. Salehpour, S, Alipour, P, Razzaghy-Azar, M, Ardeshirpour, L, Shamshiri, A, Monfared, MF, et al.. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr 2010;74:428–35. https://doi.org/10.1159/000315482.Suche in Google Scholar
14. Varimo, T, Huopio, H, Kariola, L, Tenhola, S, Voutilainen, R, Toppari, J, et al.. Letrozole versus testosterone for promotion of endogenous puberty in boys with constitutional delay of growth and puberty: a randomised controlled phase 3 trial. Lancet Child Adolesc Health 2019;3:109–20. https://doi.org/10.1016/s2352-4642(18)30377-8.Suche in Google Scholar
15. Shams, K, Cameo, T, Fennoy, I, Hassoun, AA, Lerner, SE, Aranoff, GS, et al.. Outcome analysis of aromatase inhibitor therapy to increase adult height in males with predicted short adult stature and/or rapid pubertal progress: a retrospective chart review. J Pediatr Endocrinol Metab 2014;27:725–30. https://doi.org/10.1515/jpem-2013-0470.Suche in Google Scholar
16. Kong, Y, Chen, H, Liang, L, Zheng, M, Fang, Y, Wang, C. Aromatase inhibitors combined with growth hormone in treatment of adolescent boys with short stature. Zhejiang da xue xue bao Yi xue ban. J Zhejiang Univ Med Sci. 2020;49:283–90.Suche in Google Scholar
17. Hero, M. Aromatase inhibitors in the treatment of short stature. Endocr Dev 2016;30:130–40.10.1159/000439338Suche in Google Scholar
18. Mauras, N, Ross, JL, Gagliardi, P, Yu, YM, Hossain, J, Permuy, J, et al.. Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature. J Clin Endocrinol Metab 2016;101:4984–93. https://doi.org/10.1210/jc.2016-2891.Suche in Google Scholar
19. McGrath, Niamh, Michael J O’Grady. Aromatase inhibitors for short stature in male children and adolescents. Cochrane Database Syst Rev. 2015;10. https://doi.org/10.1002/14651858.CD010888. 26447646.Suche in Google Scholar
20. Hero, M, Toiviainen-Salo, S, Wickman, S, Mäkitie, O, Dunkel, L. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res 2010;25:1536–43. https://doi.org/10.1002/jbmr.56.Suche in Google Scholar
21. Bayley, N, Pinneau, SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–41. https://doi.org/10.1016/s0022-3476(52)80205-7.Suche in Google Scholar
22. Mauras, N, Welch, S, Rini, A, Klein, KO. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 2004;17:1597–606. https://doi.org/10.1515/jpem.2004.17.12.1597.Suche in Google Scholar PubMed
23. Neely, EK, Kumar, RB, Payne, SL, Ranadive, SA, Suchet, DI. Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. J Clin Endocrinol Metab 2014;99:4086–93. https://doi.org/10.1210/jc.2014-2432.Suche in Google Scholar PubMed
24. Karmazin, A, Moore, WV, Popovic, J, Jacobson, JD. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab 2005;18:285–93. https://doi.org/10.1515/jpem.2005.18.3.285.Suche in Google Scholar PubMed
25. Lui, JC, Baron, J. Effects of glucocorticoids on the growth plate. Endocr Dev 2011;20:187–93.10.1159/000321244Suche in Google Scholar PubMed PubMed Central
26. Faglia, G, Arosio, M, Porretti, S. Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole. Would it help short children grow up? J Endocrinol Invest 2000;23:721–3. https://doi.org/10.1007/bf03345059.Suche in Google Scholar PubMed
27. Poulton, AS, Melzer, E, Tait, PR, Garnett, SP, Cowell, CT, Baur, LA, et al.. Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. Med J Aust 2013;198:29–32. https://doi.org/10.5694/mja12.10931.Suche in Google Scholar PubMed
28. Poulton, AS, Bui, Q, Melzer, E, Evans, R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. Int Clin Psychopharmacol 2016;31:93–9. https://doi.org/10.1097/yic.0000000000000109.Suche in Google Scholar
29. Biederman, J, Spencer, TJ, Monuteaux, MC, Faraone, SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr 2010;157:635–40. https://doi.org/10.1016/j.jpeds.2010.04.025.Suche in Google Scholar PubMed PubMed Central
30. Swanson, JM, Arnold, LE, Molina, BSG, Sibley, MH, Hechtman, LT, Hinshaw, SP, et al.. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 2017;58:663–78. https://doi.org/10.1111/jcpp.12684.Suche in Google Scholar PubMed PubMed Central
31. Hero, M, Wickman, S, Dunkel, L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol 2006;64:510–3. https://doi.org/10.1111/j.1365-2265.2006.02499.x.Suche in Google Scholar PubMed
© 2022 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Original Articles
- Newborn screening for propionic, methylmalonic acidemia and vitamin B12 deficiency. Analysis of 588,793 newborns
- Use of letrozole to augment height outcome in pubertal boys: a retrospective chart review
- Study of the frequency and clinical features of maturity-onset diabetes in the young in the pediatric and adolescent diabetes population in Iran
- Iatrogenic hyperthyroidism in primary congenital hypothyroidism: prevalence and predictive factors
- Utility of head CT scan in treatment decisions for suspected cerebral edema in children with DKA
- Newborn screening and genetic variation of medium chain acyl-CoA dehydrogenase deficiency in the Chinese population
- Performance of glucagon stimulation test in diagnosing central adrenal insufficiency in children when utilising the Roche Elecsys® cortisol II assay: a pilot study
- Effects and dose-response relationship of exercise training on cardiometabolic risk factors in children with obesity
- Biochemical indicators of euthyroid sick syndrome in critically ill children
- Short Communication
- Parental marital relationship satisfaction predicts glycemic outcomes in children with type 1 diabetes
- Case Reports
- Late onset Bartter syndrome: Bartter syndrome type 2 presenting with isolated nephrocalcinosis and high parathyroid hormone levels mimicking primary hyperparathyroidism
- Three pediatric cases of symptomatic hyponatremia in Prader–Willi syndrome
- Identification of a novel mutation in FGFR1 gene in mother and daughter with Kallmann syndrome
- Exaggerated mini-puberty in a preterm girl: a case report and review of literature
- Diabetic ketoacidosis masquerading behind alkalemia an undiagnosed or missed variant of diabetic ketoacidosis
Artikel in diesem Heft
- Frontmatter
- Original Articles
- Newborn screening for propionic, methylmalonic acidemia and vitamin B12 deficiency. Analysis of 588,793 newborns
- Use of letrozole to augment height outcome in pubertal boys: a retrospective chart review
- Study of the frequency and clinical features of maturity-onset diabetes in the young in the pediatric and adolescent diabetes population in Iran
- Iatrogenic hyperthyroidism in primary congenital hypothyroidism: prevalence and predictive factors
- Utility of head CT scan in treatment decisions for suspected cerebral edema in children with DKA
- Newborn screening and genetic variation of medium chain acyl-CoA dehydrogenase deficiency in the Chinese population
- Performance of glucagon stimulation test in diagnosing central adrenal insufficiency in children when utilising the Roche Elecsys® cortisol II assay: a pilot study
- Effects and dose-response relationship of exercise training on cardiometabolic risk factors in children with obesity
- Biochemical indicators of euthyroid sick syndrome in critically ill children
- Short Communication
- Parental marital relationship satisfaction predicts glycemic outcomes in children with type 1 diabetes
- Case Reports
- Late onset Bartter syndrome: Bartter syndrome type 2 presenting with isolated nephrocalcinosis and high parathyroid hormone levels mimicking primary hyperparathyroidism
- Three pediatric cases of symptomatic hyponatremia in Prader–Willi syndrome
- Identification of a novel mutation in FGFR1 gene in mother and daughter with Kallmann syndrome
- Exaggerated mini-puberty in a preterm girl: a case report and review of literature
- Diabetic ketoacidosis masquerading behind alkalemia an undiagnosed or missed variant of diabetic ketoacidosis
